Contact Us

MIRA-55

A Safe Approach to Inflammatory Pain

An oral cannabinoid analog designed to address inflammatory pain without the intoxicating effects associated with THC.

  • MIRA-55
  • Inflammatory pain
  • Advancing Toward IND
  • Preclinical

The Science

MIRA-55 Demonstrated Potent Analgesic Activity

In a validated formalin pain model, MIRA-55 significantly increased pain threshold, with activity comparable to morphine (p<0.01).

Separate Behavioral Assessments

MIRA-55 did not produce THC-like behavioral effects in a separate battery of validated assessments.

Pain Threshold (g) 0 10 20 30 40 Baseline Formalin MIRA-55 Morphine * * * * *
  • Following scientific review, the DEA determined that MIRA-55 is not classified as a controlled substance.

A Different Cannabinoid Profile Than THC

THC is a potent CB1 agonist with more modest activity at CB2. MIRA-55 has a differentiated receptor profile, with potent CB2 agonist activity and more modest CB1 activity.

Status

Advancing MIRA-55 Toward IND

MIRA-55 is advancing through preclinical development, with IND submission targeted for 1H 2027.*

*Subject to FDA clearance and other regulatory and operational factors.

Publications

Publications and Posters

View All

Explore Our Pipeline

Advancing Better Therapies, Together

Explore MIRA’s broader pipeline across pain and obesity.

View Pipeline